




RealRate

PHARMACEUTICAL 2017

Syndax Pharmaceuticals Inc
Rank 108 of 308

Syndax



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Syndax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syndax Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 104% points. The greatest weakness of Syndax Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 308%, being 63% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	108,510
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,366
Liabilities, Non-Current	14,508
Other Assets	243
Other Compr. Net Income	28
Other Expenses	0
Other Liabilities	0
Other Net Income	-706
Other Revenues	1,220
Property and Equipment	260
Research and Development	31,665
Selling, General and Administrative Expense	13,321

Output Variable	Value in 1000 USD
Assets	109,013
Liabilities	24,874
Expenses	44,986
Revenues	1,220
Stockholders Equity	84,139
Net Income	-44,472
Comprehensive Net Income	-44,458
BaseVar	90,414
ECR before LimitedLiability	208%
Economic Capital Ratio	308%